On Feb. 3, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency had granted conditional marketing authorization for Nuvaxovidﾙ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older in Great Britain.

The vaccine, also known as NVX-CoV2373, was the first protein-based vaccine to be authorized for use in Great Britain.